Merck to Acquire Terns Pharmaceuticals for $6.7 Billion | STAT+ Exclusive

Merck, a major pharmaceutical company, announced Wednesday its intention to acquire Terns Pharmaceuticals, a U.S.-based biotech firm specializing in leukemia treatment, for $6.7 billion. The deal, valued at $53 per share, represents a 6% premium over Terns’ Tuesday closing price and signals a significant move by Merck to bolster its cancer drug pipeline as it prepares for potential revenue declines from its blockbuster immunotherapy, Keytruda. Shares of Terns rose sharply on the news, reflecting investor confidence in the potential of Terns’ lead drug candidate, TERN-701.

Expanding the Portfolio Ahead of Keytruda’s Patent Expiration

The acquisition of Terns is the third multibillion-dollar deal Merck has made in the past year, demonstrating a proactive strategy to diversify its portfolio. This push is largely driven by the impending loss of patent protection for Keytruda in 2028, a drug that currently generates substantial revenue for the company. As CNBC reported, Merck is aiming to build up its pipeline of new therapies to offset the anticipated decline in Keytruda sales.

TERN-701, the key asset driving the acquisition, is currently in development for a specific type of leukemia. Analysts believe this drug has the potential to grow a significant revenue generator, potentially rivaling Novartis’ Scemblix in the market. The promising early trial results for TERN-701 have fueled investor excitement and contributed to the sixfold increase in Terns’ stock price over the last six months.

Understanding Leukemia and the Potential of TERN-701

Leukemia is a type of cancer that affects the blood and bone marrow. It’s characterized by the abnormal production of white blood cells. Notice several different types of leukemia, each with its own prognosis and treatment options. The specific type of leukemia that TERN-701 is targeting wasn’t detailed in the available sources, but the drug’s potential to compete with Scemblix suggests it’s addressing a significant unmet need in the treatment of this disease. Scemblix is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML), a type of cancer that starts in the bone marrow. STAT News highlights the potential of TERN-701 to become a major player in the leukemia treatment landscape.

The Deal’s Structure and Timeline

The acquisition will be an all-cash transaction, with Merck paying $53 per share for Terns Pharmaceuticals. The deal is expected to close in the second quarter of the year, subject to customary closing conditions, including regulatory approvals. This timeline allows Merck to integrate Terns’ research and development efforts and accelerate the development of TERN-701. The swift rise in Terns’ stock price, with a 5.3% increase on Wednesday and a peak of 15% in earlier trading, underscores the market’s positive reception to the deal.

Merck’s Recent Acquisition Activity

This acquisition is part of a broader trend of consolidation within the pharmaceutical industry. Merck has been actively pursuing strategic acquisitions to strengthen its pipeline and position itself for future growth. The company’s previous multibillion-dollar acquisitions demonstrate its commitment to innovation and its willingness to invest in promising new therapies. This strategy is particularly important as pharmaceutical companies face increasing pressure to develop new drugs and address unmet medical needs.

The Broader Context of Pharmaceutical Acquisitions

The pharmaceutical industry has seen a surge in mergers and acquisitions in recent years. Several factors are driving this trend, including the high cost of drug development, the increasing complexity of regulatory requirements, and the desire to gain access to new technologies and markets. Acquisitions allow companies to quickly expand their portfolios, reduce risk, and achieve economies of scale. Reuters initially reported on the nearing deal, highlighting the industry trend.

What Comes Next: Integration and Development of TERN-701

Following the completion of the acquisition, Merck will focus on integrating Terns’ operations and accelerating the development of TERN-701. This will involve conducting further clinical trials to evaluate the drug’s safety and efficacy, as well as preparing for potential regulatory submissions. The success of TERN-701 will be crucial for Merck as it seeks to diversify its revenue streams and maintain its position as a leading pharmaceutical company. The company will also need to navigate the complex regulatory landscape and ensure that TERN-701 meets the stringent requirements of health authorities worldwide.

The acquisition of Terns Pharmaceuticals represents a strategic investment for Merck, positioning the company to address a significant unmet need in leukemia treatment and mitigate the impact of Keytruda’s patent expiration. The coming months will be critical as Merck works to integrate Terns’ operations and advance the development of TERN-701, potentially offering a new and effective treatment option for patients battling this challenging disease.